Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AssigneeGeron Corporation
InventorsEkaterina BASSETT, Bart Burington, Hui Wang, Kevin Eng
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.
Claims20
A method of selecting an individual diagnosed with or suspected of having cancer who will benefit from treatment with a telomerase inhibitor, the method comprising:
- a. determining relative telomere length by analyzing the relative length of telomeric nucleic acids in cancer cells present in a biological sample from the individual;
- and
- b. selecting an individual who will benefit from treatment with a telomerase inhibitor when the average relative telomere length in the cancer cells present in a biological sample from the individual is determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards.
A method of treating an individual diagnosed with or suspected of having cancer, the method comprising:
- a. determining relative telomere length by analyzing the relative length of telomeric nucleic acids in cancer cells present in a biological sample from the individual;
- b. selecting an individual who will benefit from treatment with a telomerase inhibitor when the average relative telomere length in the cancer cells present in a biological sample from the individual is determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards;
- and
- c. administering a therapeutically effective amount of the telomerase inhibitor to the individual.
A method of treating an individual diagnosed with or suspected of having cancer, the method comprising:
- administering a therapeutically effective amount of a telomerase inhibitor to the individual when the average relative telomere length in cancer cells present in a biological sample from the individual has been determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards.
Dependencies are inferred from the claim text.